Ontology highlight
ABSTRACT: Background
Drugs and high-risk medical devices are increasingly likely to receive Food and Drug Administration (FDA) approval through expedited pathways, which has implications for informed treatment consent (i.e., consent in clinical practice).Objective
To obtain expert opinion about the clinical and ethical implications of the increasing availability of new drugs and devices approved through expedited development and regulatory review pathways.Design
Qualitative study using individual semi-structured videoconference interviews.Participants
National leaders in medicine, ethics, and law (n=12) with expertise in medical product regulation, payor policymaking, bioethics, physician practice, patient advocacy, public health expertise/advocacy, clinical trials, t
SUBMITTER: Dhruva SS
PROVIDER: S-EPMC9708961 | biostudies-literature | 2022 Dec
REPOSITORIES: biostudies-literature